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Abstract
Introduction: Selective decontamination of the digestive tract (SDD) is a prophylactic antibiotic regimen that is not
widely used in practice. We aimed to describe the opinions of key ‘stakeholders’ about the validity of the existing
evidence base, likely consequences of implementation, relative importance of their opinions in influencing overall
practice, likely barriers to implementation and perceptions of the requirement for further research to inform the
decision about whether to embark on a further large randomised controlled trial.
Methods: This was a Delphi study informed by comprehensive framework of possible determinants of health
professionals’ behaviour to study Critical Care practice in four countries. There were four key stakeholder participant
groups including ICU physicians, pharmacists, clinical leads, and clinical microbiologists/ infectious disease
physicians. Round one comprised participant interviews and Rounds two and three were online questionnaires
using Delphi method.
Results: In this study, 141 participants were recruited of whom 82% were retained. Participants rated themselves as
knowledgeable about SDD. Antibiotic resistance was identified as the most important issue. SDD was seen as a low
clinical priority but few participants reported strong opposition. There was moderate agreement that research to
date has not adequately addressed concerns about antibiotic resistance and lacks generalizability. Participants
indicated equipoise with regard to benefits and harms of SDD, and indicated strong support for a further
randomised trial.
Conclusions: Clinicians have clinical equipoise about the effectiveness of SDD. Future research requires longer
follow up to assess antibiotic resistance as well as greater validity/generalizability to provide definitive answers on
the effectiveness of decontamination and effects on antibiotic resistance. SDD was regarded as not being a high
clinical priority, which may limit future trial participation. These results have identified that further large randomised
controlled trial of SDD in critical care is both warranted and appropriate.
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Introduction
Hospital-acquired infections (HAI) are a major clinical
problem for modern health services because they are as-
sociated with morbidity and mortality as well as high
additional healthcare costs. Critically ill patients are ex-
tremely susceptible to such infections. Between 20% and
50% of ICU patients experience HAI [1]. Reducing the
incidence and mortality of HAI is currently the focus of
many ICU quality improvement programmes and gov-
ernment initiatives worldwide.
One intervention that has gained much attention in
reducing the incidence of HAI is selective deconta-
mination of the digestive tract (SDD). SDD involves the
application of topical nonabsorbable antibiotics to the
oropharynx and stomach, and a short course of intraven-
ous antibiotics [2-9]. The evidence supporting the use of
SDD currently comprises 12 meta-analyses of 36 rando-
mised controlled trials (RCTs) [2-9]. Many of these stud-
ies demonstrate a benefit in terms of reducing rates of
pneumonia, and more recent studies also show lower
mortality in all ICU patients or in certain subgroups. A
recent large cluster RCT of SDD conducted in the
Netherlands found a 3.5% absolute reduction in mortal-
ity [10]. A Cochrane review of SDD comprising 36 trials
demonstrated that SDD was associated with reduced
pneumonia (odds ratio 0.32 (95% confidence interval
0.26 to 0.38)) and death (odds ratio 0.75 (95% confidence
interval 0.65 to 0.87)) [9]. This mortality benefit is of the
magnitude of a 3 to 6% absolute risk reduction with a
number needed to treat of 18 to save one life [9,10]. If
the documented mortality benefit could be realised
internationally it would save tens of thousands of lives
each year.
Despite this evidence, the international ICU commu-
nity has not widely adopted SDD [11]. Little systematic
evidence is available about clinicians’ beliefs regarding
the existing evidence, the perceived benefits and risks of
SDD, the factors that influence lack of adoption, and
likely barriers to implementation [11]. Further, it is
unclear whether there is a need for further evidence of
effectiveness before use of SDD would become broadly
acceptable, and which study design would be feasible
and acceptable to clinicians.
We performed an international Delphi study to iden-
tify the opinions of key stakeholders about the strength
and generalisability of the existing evidence related to
SDD, the positive and negative consequences of imple-
menting SDD in ICUs, and the barriers to implementing
SDD in ICUs. Ultimately, we planned to use the results
of this Delphi study to inform practitioners and resear-
chers about whether a further RCT of SDD in critical care
was appropriate and warranted. To ensure the results gen-
erated would be maximally robust and systematic, we used
the Theoretical Domains Framework of clinical behaviour
developed from the field of health psychology [12,13]. The
Framework provides a model for comprehensive assess-
ment of factors affecting clinical behaviour.
Materials and methods
An international Delphi study (one qualitative interview
round and two quantitative rounds) was performed in
participants in Australia and New Zealand, Canada, and
the UK. Ethics approval was granted by the Nepean
Research Ethics Committee (Australia and New Zealand),
the Sunnybrook Hospital Research Ethics Committee
(Canada) and the North of Scotland Ethics Service (the
UK), and individual consent was obtained from all partici-
pants. All human and animal studies have been approved
by the appropriate ethics committee and have therefore
been performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its later
amendments.
Sample
A Delphi process gauges opinions from a panel of
experts [14]. For this study, we defined experts as those
in a position to exert decisional authority and be key
stakeholders with regard to ICU policy about SDD or to
lead its implementation into clinical practice (if that was
to happen). Experts were not defined as experts in SDD.
We identified four key stakeholder groups: ICU physi-
cians, ICU pharmacists, ICU clinical leads (medical and
nursing), and clinical microbiologists and infectious dis-
ease specialists who had ICU responsibility.
Our target sample size was 10 participants per stake-
holder group in each of the three geographical zones (40
per zone, 120 in total) [15]. The research team compiled
lists of their respective stakeholder groups and assessed
individuals according to predetermined diversity factors
(geographical location, ICU bed number, current SDD
practice and academic affiliation). To achieve a final sample
size of 10 in all stakeholder groups in each zone, we ini-
tially oversampled up to three participants in each of the
four groups per zone. Round 1 was a telephone-delivered
semi-structured interviewing using a topic guide developed
using the Theoretical Domains Framework. All participants
who participated in Round 1 were invited to participate in
Round 2. Only those who responded at Round 2 were
invited to participate in Round 3. Full analysis of the
Round 1 interviews of this Delphi study are reported else-
where due to the differing nature of the data (qualitative),
and the high total volume of data from the study makes
concise reporting of all data in one paper impossible [16].
Development of the Delphi materials
Use of the Theoretical Domains Framework
Construction of the Delphi materials was directly informed
by the Framework, a comprehensive characterisation of
Cuthbertson et al. Critical Care 2013, 17:R266 Page 2 of 13
http://ccforum.com/content/17/6/R266
possible determinants of health professionals’ behaviour.
The Framework was developed out of a collaboration of
health psychologists and implementation researchers, and
has been used in other clinical spheres to systematically
assess barriers and facilitators to the uptake of specific
clinical behaviours [12]. The framework clusters determi-
nants of health professionals’ behaviour into 12 salient
domains (Table 1). The domains explore the effect of
issues including knowledge (that is, how a clinician’s
knowledge about a topic affects his/her behaviour), social/
professional role and identity (how the accepted clinical
thinking and norms of a particular profession affect a
clinician’s behaviour), and beliefs about consequences
(that is, how a clinician’s perception of the benefits and
harms of a clinical action affects his/her behaviour).
An added benefit of the Theoretical Domains Frame-
work is that future research, if any, is guided by the
theoretical domains identified as most crucial to the use
of SDD. For example, if the beliefs about consequences
domain was identified as most important, this would
suggest that there are continuing uncertainties about the
evidence base and that further research on clarifying the
evidence base is required.
We ensured that all opinions raised in all regions in
Round 1 were taken forward to Round 2 as items. Fifty-
six items were generated in Round 1, 46 of which were
common across all regions [16] and were included in
Round 2 and Round 3 materials for the entire sample. In
addition, five items with multiple response options were
included in Rounds 2 and 3 to explore specific trial design
and feasibility issues.
The Delphi rounds
Round 1 of the Delphi study involved semi-structured
Theoretical Domains Framework-based interviews, ana-
lysed using content analysis. The set of 56 statements
summarising beliefs about SDD generated from inter-
view data were included in the instrument used for
Round 2 and Round 3 reported in this paper. Item word-
ing (that is, in favour of/against SDD) was selected as
follows: using participants’ wording from Round 1 inter-
views; creating balance (positive and negative statement
directions) among items; and reflecting best practice in
terms of constructing questionnaire items. This resulted
in eight positively worded items (that is, in favour of
SDD use), 33 negatively worded items (that is, concerns
about SDD use) and 11 neutrally worded items. For each
item, there were two questions: ‘To what extent do you
agree or disagree?’ (on a nine-point Likert scale, with
1 = ‘strongly disagree’ and 9 = ‘strongly agree’) and ‘How
important is this issue is in your overall opinion about the
delivery of SDD to critically ill patients?’ [17]. Five further
questions were included to measure views about further
SDD research (Additional file 1).
The Round 2 questionnaire was piloted with five clini-
cians not participating in the Delphi study and led to
Table 1 Explanations of the twelve theoretical domains used to generate Round 1 data
Domain label [12] Domain content
Beliefs about consequences Often regarded as core to clinical reasoning, this domain covers the perceived benefits
and harms of a clinical action. In some contexts it can also include consequences for
the clinician such as workload, pay, career progression, or for the hospital or health service.
Behavioural regulation Includes the ‘how’ of changing clinical practice: what are the practical strategies that would
facilitate or hinder uptake of a new practice.
Beliefs about capabilities How confident clinicians are that they could change their practice effectively.
Emotion Includes issues such as work stress, patient anxiety and other emotional factors that may
help or hinder the uptake of new approaches to care.
Environmental context/resources Includes the physical (including financial) issues that may limit change, including staffing
levels and time as well as equipment or space.
Knowledge Knowledge of the field (that is, whether there is adequate evidence) and individuals’
knowledge of the evidence or of a guideline.
Memory, attention and decision processes The level of attention that is needed to perform the key clinical action (that is, whether
forgetting is likely to be a problem) and the processes by which clinical decisions are
made by individuals and teams.
Motivation and goals The relative priority that is given to one clinical issue, compared with other demands.
Social/professional role and identity The clinical thinking and norms of a particular profession.
Skills Covers the possibility that new skills would be required by the staff that are required to
implement a new procedure.
Social influences The influence of other individuals or groups on clinical practice; for example, patients,
patients’ families, pressure groups.
Nature of the behaviours Some new practices are very similar to current practice and so are easier to implement
than new practices that require a dramatic change in ways of working.
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minor changes only. In Round 3 the same questionnaire
was used together with feedback about the participant
cohort responses to each question, a reminder of their
own previous response and a request to rate the item
again. Emails were sent to all Round 1 participants with
individual links to the online questionnaire. Responses
were monitored and reminders sent on two occasions
within the month.
With regard to consensus, in this study we were inter-
ested not only in the proportion of participants who
agreed with each item, but also the proportion of partici-
pants who were uncertain about their agreement with
the items. Levels of consensus for the question ‘To what
extent do you agree or disagree’ were assessed by not-
ing the highest percentage of participants whose scores
fell within any three-point band on the nine-point
scale [18].
Data management and analysis
Descriptive statistics were calculated for participant
demographics and for each statement, including the
mean, median and interquartile range (IQR). We mea-
sured stability of opinions across rounds, both at indi-
vidual participant and group response levels. At the
group level, stability for each item was assessed by com-
puting the change in arithmetic means across the whole
sample from Rounds 2 and 3. A change of one point in
the mean agreement level was deemed a potentially
important change in opinion. At the individual level,
stability was measured using individual change scores,
such that a score of zero signified identical responses in
Rounds 2 and 3.
Results
Participants
We recruited 141 participants into Round 1 and retained
118 to the end of Round 3 (82% retention) [16]. The
breakdown of participation by stakeholder group and
retention in the study is displayed in Additional file 2.
Median years in practice was 15 (IQR 11 to 21) and
median number of ICU beds was 20 (IQR 15 to 28), with
109 participants working in academic/academic-affiliated
centres and nine in nonacademic centres.
Participants’ self-reported knowledge of SDD
Participants’ perception of their own knowledge was
measured with the item ‘I know the SDD evidence base
well enough to have an informed opinion of its use’.
Overall, participants rated themselves as knowledgeable
about SDD (median score ≥6). However, 37 (31%) rated
themselves <5 on the nine-point scale. Participants
reporting a low level of perceived knowledge in Round 2
showed greater change in their responses from Round 2
to Round 3 (mean change 0.19, standard deviation 0.19)
than participants whose perceived knowledge was >5
(mean change 0.09, standard deviation 0.13; P = 0.002).
Stability of opinions
There was high stability of responses from Round 2 to
Round 3, both at the individual level (>69% of change
scores in the range −1 to +1) and at the group level
(mean differences ranging from 0 to 0.52). Stability
across stakeholder groups showed there was a greater
level of change from Round 2 to Round 3 in the clinical
lead group (mean 0.18, standard deviation 0.2) than in
other stakeholder groups (means 0.09 to 0.11, standard
deviation 0.16 to 0.2; P = 0.044).
What was important to responders?
Questions rated as most important by participants are
presented in Table 2. Two questions on antibiotic re-
sistance were in the top three for importance. The validity
of self-reported importance is a key issue as the ratings
represent participant’s opinions and could be thought of
Table 2 Most important items after Round 3 of the Delphi
Domain of TDF [12] Item stem Median (IQR)
Beliefs about consequences SDD increases antibiotic resistance 8 (7 to 9)
Decision processes The decision to adopt SDD requires consensus between my colleagues 8 (7 to 9)
Knowledge Research to date has not adequately addressed concerns about antibiotic resistance and SDD 8 (7 to 9)
Decision processes The decision to adopt SDD requires a review and appraisal of the current best evidence 8 (7 to 9)
Behavioural regulation My hospital tries to reduce antibiotic use 8 (7 to 9)
Decision processes Part of the decision to adopt SDD requires agreement about which patients will receive it 8 (7 to 9)
Beliefs about consequences SDD would increase ICU Clostridium difficile infections 8 (6 to 8)
Knowledge I know the SDD evidence base well enough to have an informed opinion regarding its use 8 (6 to 8)
Motivation We are addressing hospital-acquired infections using other strategies 7 (6.5 to 9)
Motivation We are addressing ventilator-associated pneumonia using other strategies 7 (7 to 8)
Data presented as medians and interquartile ranges on scale of 1 to 9 (1 = ‘strongly disagree’ and 9 = ‘strongly agree’). IQR, interquartile range; SDD, selective
decontamination of the digestive tract; TDF, Theoretical Domains Framework.
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as low level of evidence. However, in support of validity,
we found a high level of congruence between these impor-
tance ratings and other indicators of importance [19].
Opinions about SDD
Very few participants reported strong opposition to SDD
(although scores ranged from 1 to 9; Figure 1). Participants
indicated that their hospitals tried to reduce antibiotic use,
reduce the widespread use of other strategies for tackling
HAI, had low ventilator-associated pneumonia (VAP) rates
and the lack of clinical priority for SDD (Figure 1). More
items related to this topic are reported in Additional file 1.
Opinions on the validity and adequacy of the evidence
base and the consequences of implementing SDD
There was moderately strong agreement (median 7, IQR 6
to 8) that research to date has not adequately addressed
concerns about antibiotic resistance, and that the evidence
base is not generalisable (Figure 2). There was low-level
agreement (median 6, IQR 5 to 7) that SDD increases
antibiotic resistance but neutrality about whether SDD
increases Clostridium difficile, whether SDD benefits the
patients to whom it is delivered and whether the risks of
SDD outweigh the benefits. More items related to these
topics are reported in Additional file 1. Generally, these
responses suggest clinical equipoise relating to the benefits
and harms of SDD.
Opinions about the likely barriers to implementation
There was strong agreement that the decision to adopt
SDD requires consensus amongst colleagues (median 9,
IQR 8 to 9), appraisal of the current evidence base
(median 9, IQR 8 to 9), and agreement on which patients
will receive SDD (median 8, IQR 8 to 9). There was strong
agreement (median 9, IQR 8 to 9), that the skills to ad-
minister SDD fall within existing clinical competencies
(Figure 3). Participants reported their perceptions of con-
flicting opinions on antibiotic use among microbiology
and intensive care physicians (Additional files 3 and 4).
Opinions on feasibility of further research
There was strong agreement from participants regarding
the need for an international RCT of SDD but there was
significant variability with regard to the impact of con-
cerns about antibiotic resistance on willingness to partici-
pate (Figure 4). Participants felt it was ethically acceptable
to conduct further RCTs evaluating the effectiveness of
SDD (median 8, IQR 7 to 9). Participants were in favour
of mortality as a primary outcome, a cost–benefit analysis,
monitoring of antibiotic resistance before, during and after
the trial, and a control arm that would include either VAP
bundles (the UK and Canada) or usual care (Australia/
New Zealand) (Figure 4). More items related to this topic
are reported in Additional file 1.
Comparisons between stakeholder groups
We compared responses from the four different stake-
holders groups for the items ‘I am opposed to SDD’ and
‘The risks of SDD outweigh the benefits’. For ‘I am oppo-
sed to SDD’, ICU physicians had a median 5 (IQR 3 to 5),
microbiologists a median 6 (IQR 5 to 7), ICU pharmacists
a median 5 (IQR 4 to 5) and clinical leads a median 5
(IQR 3 to 5). For ‘The risks of SDD outweigh the benefits’,
ICU physicians had a median 3 (IQR 2 to 5), microbiolo-
gists a median 5 (IQR 4 to 7), ICU pharmacists a median
5 (IQR 3 to 6) and clinical leads a median 3 (IQR 2 to 5).
Figures are presented in Additional files 3 and 4.
Discussion
This is the first study to rigorously examine barriers to
implementation of SDD and the first to examine these
barriers with an international perspective. We also believe
that using the Delphi technique to inform the decision to
undertake a further large RCT is novel.
Opinions about SDD
We did not find significant opposition to SDD despite
agreement that the evidence base is currently seen as
unconvincing and the fact that very few centres have
implemented SDD. Participants identified that their hos-
pitals were currently targeting VAP and HAI using other
methods, and SDD was not a topic of clinical discussion.
This perceived low priority of SDD could act as a major
challenge to SDD implementation or to the performance
of a future trial. When we analysed differences between
key stakeholder groups we found that microbiologists
were more likely to be opposed to SDD and, along with
ICU pharmacists, were more likely to think that ‘the
risks of SDD outweigh the benefits’. This could be ex-
plained by the microbiologists and the ICU pharmacists
having a more ecological view on antibiotic usage whereas
ICU clinicians may be more able to identify with the
individual patient benefits.
Opinions about the evidence base
Participants were not persuaded of the internal or exter-
nal validity of the evidence base and demonstrated clin-
ical equipoise with regard to the benefits and harms of
SDD. We conducted a detailed examination of responses
in the UK data to check whether equipoise was asso-
ciated with poor knowledge of the evidence base, and
found that the mid-point on the beliefs about conse-
quences items was endorsed by a large proportion of
participants (n = 21) who assessed their knowledge of
the evidence base as high. Hence, equipoise was unlikely
to have arisen from ignorance of the evidence base.
Superficially, this equipoise would seem surprising in the
presence of such a large evidence base suggesting mor-
tality benefit [9], but since the literature to date does not
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Figure 1 Opinions about the relevance of selective decontamination of the digestive tract. Response format: 1 = ‘strongly disagree’ to
9 = ‘strongly agree’. y axis, percentage of responders. SDD, selective decontamination of the digestive tract; VAP, ventilator-associated pneumonia.
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Figure 2 Opinions on the internal and external validity and adequacy of the existing evidence base for selective decontamination
of the digestive tract (SDD) and the likely consequences of implementing SDD in ICUs. Top two graphs: opinions on the internal and
external validity and adequacy of the existing evidence base for selective decontamination of the digestive tract (SDD). Bottom four graphs:
opinions on the likely consequences of implementing SDD in ICUs. Response format: 1 = ‘strongly disagree’ to 9 = ‘strongly agree’. y axis,
percentage of responders.
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clearly identify the effects of SDD on key issues such as
antibiotic resistance, this seems a reasonable stance and
is a key external validity issue. That said, evidence to
date does not suggest harmful effects of SDD on anti-
biotic resistance [20]. The findings about equipoise have
clear implications for further research. If there is cer-
tainty about the benefits of a clinical intervention, it is
regarded as unethical to conduct further evaluation by
randomising patients to a usual care control group [21].
Consistent with this principle, there was a high level of
agreement that it would be ethically acceptable to con-
duct further SDD research.
It is interesting to compare the evidence base for SDD
(which has not been widely implemented) with the
evidence for low-dose steroids [22] or tight glycaemic
control [23]. SDD remains not widely implemented
despite a large (although clearly incomplete) evidence
base, whereas low-dose steroids in septic shock and tight
glycaemic control were implemented extraordinarily
widely with only one supportive RCT and, in the case of
steroids, previous evidence of harm [24]. This possibly
suggests that extra-scientific factors are at play in such
examples.
Barriers to implementation
This finding of clinical equipoise was confirmed when
we identified that issues related to benefits and harms of
SDD were also the most important barriers to imple-
mentation. The decision process (to adopt) and consen-
sus development were also identified as barriers. The
need for appraisal of evidence was also identified as a
barrier, which seems surprising considering the high
number of meta-analyses in the literature. These issues
may explain the very low levels of implementation to date,
with no ICUs in Canada, Australia and New Zealand
currently undertaking SDD and only 5% of ICUs in the
UK undertaking SDD (RR Canter, S Harvey, DA Harrison,
et al., Survey and observational analysis of current use of
selective decontamination of the digestive tract in UK
critical care units, British Journal of Anaesthesia 2013,
submitted). Other practice issues such as ease of delivery,
skills, patient side-effects and cost were not identified as
barriers. Nursing and pharmacy workloads were identified
as likely to increase but were not identified as barriers as
such. Few participants delivered SDD in their practice and
were therefore not ideally placed to make these assess-
ments. Interviews with clinical staff in centres delivering
SDD provided a similar perspective [25]. These results
indicate the need for new research to address the on-
going uncertainties with the evidence base, followed by
high-quality translation research if future studies suggest
benefit without harmful effects on antibiotic resistance
patterns.
Future research
We found a very high level of agreement that further
SDD research was ethical, and most participants would
support their centre being involved in a RCT to evaluate
the effectiveness of SDD. The potential of SDD to in-
crease antibiotic resistance, despite being identified as a
very important issue, would not necessarily limit trial
participation. There were high levels of agreement that
such a trial should include pre-trial, during-trial and
post-trial monitoring of antibiotic resistance, however.
Mortality was favoured as the primary outcome, with a
cost–benefit analysis seen as desirable. It is clear with
the strong weighting participants gave to antibiotic resis-
tance that this outcome needs to be given equal stance
in any future studies. Participants identified that the
control arm should receive VAP bundles in the UK and
Canada, and usual care in Australia and New Zealand.
This could be influenced by the lack of national VAP
guidelines in Australia or New Zealand. Further data on
trial design issues were identified during contemporary
interviews of intensive care triallists as another part of
our research programme (JJ Francis, EM Duncan, ME
Prior, GS MacLennan, SU Dombrowski, G Bellingan, MK
Campbell, MP Eccles, L Rose, KM Rowan, R Shulman,
APR Wilson, BH Cuthbertson, Selective decontamination
of the digestive tract in critically ill patients treated in
intensive care units: a mixed-methods feasibility study
(the SuDDICU study), Health Technology Assessment
2013, in press). Such data can help inform practitioners
and researchers on the need, appropriateness and design
of future research.
Strengths and limitations
A strength of this study was its grounding in a theoret-
ical framework that enabled us to distinguish between
factors related to the clinical evidence and potential bar-
riers related to more practical issues to do with profes-
sional roles, resources and the management of change.
Further strengths of this study were inclusion of four
key clinical stakeholder groups with influence on SDD
policy or delivery, thereby enabling a wide range of
professional opinions from those likely to influence local
policies. The study was completed by 118 clinicians from
the four different groups from three geographical regions
with high retention across rounds, making this the largest
Delphi study to date in intensive care to our knowledge.
There was evidence of high stability of responses be-
tween Rounds 2 and 3, indicating that, when given three
opportunities to consider their opinions, and viewing the
spread of opinions across the cohort, participants re-
ported consistent opinions about SDD over time. Indices
of stability may mask individual instability if different
stakeholder groups change their opinions in opposite
directions. In this study there was evidence of stability at
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Figure 3 Opinions about the likely barriers to implementing selective decontamination of the digestive tract in ICUs. Response format:
1 = ‘strongly disagree’ to 9 = ‘strongly agree’. y axis, percentage of responders. MM/ID, microbiologist/infectious disease specialists; SDD, selective
decontamination of the digestive tract.
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Figure 4 Opinions on the feasibility of further selective decontamination of the digestive tract research and whether professional
groups are likely to participate. Response format: 1 = ‘strongly disagree’ to 9 = ‘strongly agree’. y axis, percentage of responders. SDD, selective
decontamination of the digestive tract; VAP, ventilator-associated pneumonia.
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both the individual and group levels. This enhances our
confidence that the identified opinions will be relevant
over time, unless the profile of evidence, or the know-
ledge of the evidence, changes.
It is rare in Delphi studies to identify consensus around
uncertainty (for example, in the range 4 to 6 on the nine-
point scale), where this exists, and to contrast this with
consensus around agreement (range of 7 to 9 on the nine-
point scale). Given the overarching objective of the study,
consensus around uncertainty was of great importance.
Self-rated knowledge of the field was generally high,
although one-third of the participants rated their know-
ledge of the evidence base as uncertain or low. This
variation in knowledge of the evidence base is a potential
limitation of the study because it makes stated uncer-
tainty difficult to interpret. There has been longstanding
debate regarding the meaning of the neutral response in
Likert scales [26]. This point is important because it
could lead to an incorrect assessment of the presence of
equipoise and the move to conduct a new clinical trial of
SDD if neutral scores on key items were interpreted as
equipoise or uncertainty when actually they could reflect
lack of knowledge. By close scrutiny of the data we have
identified that participants who rated their SDD know-
ledge as high were strongly represented among those
who endorsed the neutral response relating to the con-
sequences of SDD, reflecting clinical equipoise. We did
not ask any questions about the participants’ views on
the play off between mortality benefit and antibiotic
resistance rates, but a separate publication reports on
this point from the perspective of the ethical issues
discussed by the participants.
Other weaknesses include the risk that our sampling
framework failed to capture all important opinions on
this subject. However, evidence from one randomised
study indicates that the Framework can result in the
generation of a wider range of opinions than using more
open approaches to eliciting opinion [27]. Furthermore,
in the Round 2 and Round 3 questionnaires we included all
opinions emerging from the Round 1 interviews, including
minority opinions, to ensure that all opinions were con-
sidered by all participants in the questionnaire rounds.
The sample size was appropriate for a Delphi study but
was numerically small when considering the scale of clin-
ical practice across the four nations. Finally, the sample
was taken from English-speaking countries only. Although
these countries are widely geographically situated, we ac-
knowledge that this is a limitation of our study.
Conclusions
This theory-informed, international assessment of opin-
ions about SDD has shown that further clinical research
in this area needs to have significantly greater validity
and generalisability. Clinicians do not currently plan to
implement SDD into their practice without further
supportive evidence. Future research needs to provide
definitive answers on the clinical effectiveness of SDD,
including in clinical environments with existing high
antibiotic resistance rates, and on the effects of SDD on
antibiotic resistance patterns (where endemic rates of
antibiotic resistance are already high). It is clear from
our study that any trial should include monitoring of
antibiotic resistance before, during and after the trial.
Mortality was favoured as the primary outcome and a
control arm receiving VAP bundles or standard care was
favoured. However, the topic was not seen currently as
high priority and this may limit interest in future SDD
trials. Any proposed future trials of SDD should take
these factors into account.
Key messages
 The evidence base for the effectiveness of SDD is
strong but SDD will not be more widely
implemented without further supportive evidence.
 Participants believe that further clinical research in
this area needs to have significantly greater validity
and generalisability.
 Further research must include monitoring of
antibiotic resistance rates before, during and after
the trial.
 SDD was not seen as a high priority and this could
limit interest in further research.
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